- Home
- ADCT vs CERS Comparison
ADCT vs CERS Comparison
Compare ADCT & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADCT
- CERS
- Stock Information
- Founded
- ADCT 2011
- CERS 1991
- Country
- ADCT Switzerland
- CERS United States
- Employees
- ADCT N/A
- CERS N/A
- Industry
- ADCT Biotechnology: Pharmaceutical Preparations
- CERS EDP Services
- Sector
- ADCT Health Care
- CERS Technology
- Exchange
- ADCT Nasdaq
- CERS Nasdaq
- Market Cap
- ADCT 241.0M
- CERS 271.4M
- IPO Year
- ADCT 2020
- CERS 1997
- Fundamental
- Price
- ADCT $3.17
- CERS $1.47
- Analyst Decision
- ADCT Strong Buy
- CERS Strong Buy
- Analyst Count
- ADCT 6
- CERS 2
- Target Price
- ADCT $7.80
- CERS $3.50
- AVG Volume (30 Days)
- ADCT 913.9K
- CERS 1.1M
- Earning Date
- ADCT 08-05-2025
- CERS 07-31-2025
- Dividend Yield
- ADCT N/A
- CERS N/A
- EPS Growth
- ADCT N/A
- CERS N/A
- EPS
- ADCT N/A
- CERS N/A
- Revenue
- ADCT $75,817,000.00
- CERS $185,144,000.00
- Revenue This Year
- ADCT $11.75
- CERS $20.97
- Revenue Next Year
- ADCT $10.29
- CERS $15.55
- P/E Ratio
- ADCT N/A
- CERS N/A
- Revenue Growth
- ADCT 10.49
- CERS 13.06
- 52 Week Low
- ADCT $1.05
- CERS $1.12
- 52 Week High
- ADCT $4.13
- CERS $2.54
- Technical
- Relative Strength Index (RSI)
- ADCT 59.73
- CERS 55.09
- Support Level
- ADCT $2.66
- CERS $1.45
- Resistance Level
- ADCT $3.30
- CERS $1.56
- Average True Range (ATR)
- ADCT 0.20
- CERS 0.08
- MACD
- ADCT 0.01
- CERS 0.01
- Stochastic Oscillator
- ADCT 90.00
- CERS 64.06
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.